Issue #157

June Medtech: 2 Top-Rated Surgical Tool Plays

The healthcare sector is undergoing a quiet but massive transformation, driven not by speculative biotech breakthroughs, but by the essential equipment and daily supplies that keep global medicine running. While high-growth tech captures the headlines, the backbone of modern medicine relies on physical infrastructure—the surgical tools, diagnostic equipment, and specialized medical devices that hospitals and clinics cannot function without. As global demographics shift and healthcare systems demand greater efficiency, the companies supplying these critical tools are seeing sustained, non-cyclical demand.

This is where the healthcare conversation shifts from clinical trials to critical infrastructure—and where some of the most resilient, cash-generating investment opportunities are found.

👉 One company is the premier supply chain partner and equipment provider for global healthcare systems, acting as the indispensable logistics backbone for hospitals and clinical facilities.

👉 The other is a global leader in specialized medical devices, dominating high-margin, high-barrier niches in vision care and women's health.

👉 Both are highly profitable, deeply integrated into global healthcare networks, and positioned to benefit from permanent demographic tailwinds.

In this edition, we break down why Medline Inc. (MDLN) and The Cooper Companies, Inc. (COO) represent two of the strongest medical device stocks on the market today—and how they provide defensive, long-term growth for your portfolio.

Important SpaceX PREDICTION

The biggest IPO in stock market history could go live as soon as June 12th - and trading legend Jon Najarian says everyone's about to make the same mistake.

The real story isn't SpaceX. It's a strange new FCC filing Elon quietly submitted earlier this year - one Morgan Stanley estimates could be worth $40 trillion.

Bigger than Tesla, xAI, Starlink, X, Neuralink, and SpaceX combined.

Click here for the full breakdown

---

Medline Inc. (NASDAQ: MDLN) operates as a premier player in the healthcare sector, specifically categorized within the Health Care Equipment & Supplies sub-industry. The company is a leading provider of medical devices, diagnostic equipment, surgical supplies, and comprehensive supply chain solutions to healthcare systems, hospitals, nursing homes, and clinical facilities globally. By acting as both a high-volume manufacturer and a logistics powerhouse, Medline ensures that critical medical supplies are delivered efficiently to the front lines of patient care. In an era where healthcare systems are facing unprecedented operational pressures, Medline's dual role as a product creator and a distribution partner positions it as an indispensable backbone of the modern medical infrastructure.

Business Model and Revenue Streams 📦

Medline’s business model is built on a foundation of high-volume manufacturing, clinical product design, and sophisticated logistics management. Unlike pure-play medical device companies that focus solely on high-margin, niche clinical equipment, or pure-play distributors that act merely as middlemen, Medline blends both worlds. The company produces a vast catalog of proprietary medical products—ranging from surgical packs, gloves, and protective apparel to advanced wound care therapies and diagnostic instruments—while simultaneously distributing third-party medical products. This comprehensive approach allows Medline to capture revenue across multiple touchpoints in the healthcare supply chain, serving as a single-source partner for complex hospital networks.

A central pillar of the company's market strategy is its proprietary Prime Vendor model. Under this framework, healthcare systems enter into long-term, exclusive or semi-exclusive agreements with Medline to streamline their entire purchasing pipeline. Instead of managing relationships with dozens of individual medical supply vendors, hospitals utilize Medline as their primary point of contact, warehouse, and logistics coordinator. This model was historically focused on the United States, but the company has recently embarked on a major international expansion strategy. A key milestone in this global push occurred on May 29, 2026, when Medline announced a landmark agreement with Mohawk Medbuy in Canada. This partnership represents a first-of-its-kind Prime Vendor relationship outside of the United States, proving that Medline's domestic supply chain efficiencies can be successfully exported to international single-payer and regional healthcare systems.

To support this massive distribution network, Medline heavily invests in cutting-edge logistics and warehouse automation. A prime example of this operational focus is the company's deployment of a state-of-the-art AutoStore robotic installation at its distribution center in Aurora, Colorado, announced on May 18, 2026. AutoStore is an advanced, high-density grid-based picking system that utilizes autonomous robots to retrieve inventory. By integrating this technology, Medline significantly reduces order preparation times, optimizes warehouse space, and mitigates the impact of ongoing labor shortages. This technological edge is critical for maintaining high service levels while keeping operational expenditures in check.

Furthermore, Medline continuously seeks out adjacent, high-margin market segments to diversify its revenue stream. On May 20, 2026, the company announced a strategic expansion of its animal health portfolio by launching specialized spay/neuter surgical packs. These ready-to-use surgical packs are designed specifically for veterinary clinics and animal welfare organizations, helping them reduce prep time, improve inventory management, and focus more on patient care. This move highlights Medline's ability to repurpose its core medical manufacturing expertise into high-growth, non-human healthcare sectors, opening up fresh, high-margin revenue channels.

From a macroeconomic perspective, Medline’s business model is highly defensive yet sensitive to broader economic policies. The demand for basic medical supplies is largely inelastic; patients require surgeries, wound care, and clinical diagnostics regardless of whether the economy is in a recession or an expansion. However, current macroeconomic headwinds—such as elevated interest rates, persistent wage inflation in the healthcare sector, and shifting trade policies—do impact the company. High interest rates increase the cost of capital for hospital systems, forcing them to delay major capital expenditures and focus intensely on operational cost reduction. This environment actually acts as a tailwind for Medline’s Prime Vendor model, as cash-strapped hospitals look to consolidate vendors to save money. Conversely, inflationary pressures on raw materials, shipping, and labor can compress Medline's operating margins if they cannot be fully passed along to customers. Additionally, changes in government reimbursement policies and hospital purchasing regulations remain a key variable that the company must navigate continuously.

Recent Performance and Corporate Developments 📈

Q1 2026 Financial Highlights: 💰

• Revenue: $7,352,000,000 ($7.35 billion) for the quarter ended March 31, 2026, representing a solid year-over-year growth rate of 10.66%.
• Net Income: $129,000,000 ($129 million) for the first quarter of fiscal 2026.
• Diluted Earnings Per Share (EPS): $0.16.
• Net Profit Margin: Approximately 1.75%, reflecting the high-volume, low-margin nature of large-scale medical distribution and supply chain services.
• Segment Growth: Solid performance driven by the expansion of the Prime Vendor model and the introduction of new proprietary product lines, though specific segment-by-segment revenue breakdowns were not detailed in the latest quarterly release.

Strategic Initiatives and Mergers: 🤝

While Medline has not announced any major corporate mergers or acquisitions in the most recent quarter, the company has been highly active in optimizing its capital structure and expanding its operational footprint. A major development occurred in late May 2026, when Medline announced the launch and subsequent closing of an upsized secondary offering of its Class A common stock. On May 20, 2026, the company initiated the offering, which was priced on May 21 and officially closed on May 28, 2026.

The transaction involved the sale of 72,554,594 shares of Class A common stock by selling stockholders affiliated with prominent private equity firms, including Blackstone Inc. and Hellman & Friedman LLC. Because this was a secondary offering, Medline did not issue any new shares and did not receive any proceeds from the sale. While such a massive block of shares entering the public market can create temporary downward pressure on the stock's price action due to increased supply, it represents a healthy transition of ownership from private equity sponsors to public institutional investors. This transition significantly increases the stock's public float and liquidity, making it more attractive to major mutual funds and institutional asset managers who require high daily trading volumes.

On the operational front, the company’s strategic partnership with Mohawk Medbuy in Canada marks a crucial step in proving its business model can scale internationally. By securing this first-of-its-kind international Prime Vendor agreement, Medline is laying the groundwork for future expansion into other global markets. Additionally, the continued rollout of automated distribution facilities, such as the AutoStore installation in Aurora, Colorado, and the expansion of the animal health portfolio with specialized surgical packs, demonstrate a disciplined approach to organic growth and operational efficiency.

Profitability and Fair Value 🎯

Analyzing Medline's profitability requires a clear understanding of the medical distribution industry's structural dynamics. With a quarterly revenue of over $7.35 billion and a net income of $129 million, Medline operates on thin net margins of approximately 1.75%. This is entirely normal for companies that manage massive physical supply chains and distribute third-party goods. The key to long-term profitability for Medline lies in its ability to shift its product mix toward higher-margin, proprietary manufactured products and to squeeze out operational inefficiencies through automated logistics systems like AutoStore.

From a valuation perspective, Medline currently trades at a trailing twelve-month (TTM) Price-to-Earnings (P/E) ratio of 30.37, with some financial databases reporting a normalized P/E ratio of 28.86. Given the company's steady but moderate net income, this P/E multiple suggests that the market is pricing in stable, defensive growth. The company’s Price-to-Sales (P/S) ratio stands at an attractive 1.04 (with some normalized ratios at 0.99), indicating that investors are paying roughly $1 for every $1 of revenue the company generates. For a business with a highly recurring revenue stream and deep hospital integration, a P/S ratio near 1.0x provides a significant margin of safety.

However, the company's Price-to-Earnings-to-Growth (PEG) ratio is elevated at 11.35, reflecting a premium valuation relative to near-term earnings growth. This high PEG ratio is common among defensive, large-cap healthcare stocks, where investors are willing to pay a premium for stability and cash flow visibility rather than explosive earnings expansion. The Enterprise Value-to-EBITDA (EV/EBITDA) ratio stands at 13.26, which is highly reasonable and in line with industry peers.

Over the past year, Medline's stock has experienced a price decline of -12.80%. This pullback is largely attributable to the market digesting the massive secondary offering of over 72 million shares by major private equity backers, which naturally created a short-term supply overhang. Now that this upsized offering has closed, this technical headwind is clearing. At a current price of $35.75, the stock appears to be fairly valued to slightly undervalued. The combination of double-digit revenue growth (10.66% YoY), clearing technical pressure, and a defensive business model makes the current price an attractive entry point for long-term investors seeking stability.

Analyst Estimates and Ratings 📊

Medline enjoys strong support from the investment community, particularly among institutional analysts who appreciate the company's defensive characteristics and market leadership. The stock currently boasts a highly favorable analyst consensus, reflecting significant buy-side interest.

Consensus Rating: 12 Buy ratings, 2 Hold ratings, 0 Sell ratings (based on a 6-month consensus).

Price Target: While specific average price targets are not detailed in the current research packet, the stock’s consensus rating is overwhelmingly positive, with zero sell ratings on the books.

Recent Upgrades / Actions: Over the last 90 days, there have been 0 formal rating upgrades, but the latest street action has consistently graded the stock as an "Outperform."

The average daily trading volume for Medline stands at a highly liquid 13,522,315 shares, easily exceeding the 500,000-share threshold preferred by institutional investors. This deep liquidity ensures that large positions can be entered or exited without causing disruptive price action. The stock's strong buy-side backing is a key driver for its inclusion in premium portfolios, as analysts view the recent price correction as a buying opportunity rather than a fundamental decay.

Investor-Focused Takeaway: Is TICKER Right for Your Portfolio?

What to Watch in the Near Term: 📈

• Q2 2026 Earnings & FY 2026 Guidance Update (July 28, 2026): This upcoming catalyst will provide critical insight into whether the company is successfully maintaining its 10.66% revenue growth and if warehouse automation is beginning to expand net margins.
• US Reimbursement & Hospital Purchasing Policy Developments (September 15, 2026): Any regulatory updates regarding Medicare, Medicaid, or private insurance reimbursement rates can directly influence hospital capital budgets and purchasing behavior.
• Q3 2026 Earnings & Initial 2027 Outlook Commentary (October 27, 2026): This event will give investors their first look at management's expectations for the upcoming fiscal year, particularly regarding international expansion and macro trends.
• International Expansion Metrics: Investors should closely monitor the progress of the Mohawk Medbuy partnership in Canada to see if the Prime Vendor model can successfully generate high-margin growth outside the US.

Recommendation:

Medline Inc. (NASDAQ: MDLN) presents a compelling, defensive opportunity for investors looking to anchor their portfolios with a stable healthcare giant. The company’s recent 10.66% year-over-year revenue growth proves that its core business remains robust, even in a challenging macroeconomic environment. While the net profit margin of 1.75% is thin, Medline is actively addressing this by deploying robotic automation like the AutoStore system and expanding into higher-margin areas like animal health and proprietary medical devices.

The recent -12.80% one-year price decline should not be viewed as a red flag; rather, it was a technical correction driven by a massive, non-dilutive secondary offering by private equity sponsors. With that supply overhang now resolved and the stock trading at a reasonable P/S ratio of 1.04, the risk-to-reward ratio is highly favorable. However, investors seeking explosive, short-term capital gains may find the stock's high PEG ratio and slow margin expansion frustrating. For patient, long-term investors looking for a highly liquid, defensive asset with institutional backing and a clear path to global expansion, Medline represents a solid, balanced addition to a diversified portfolio.

REVEALED: Trump just green-lit what could be the biggest AI budget in history.

Over $1 trillion aimed at AI-powered defense, surveillance, and autonomous weapons.

But the real money isn't in fighter jets..

It's in the small AI company supplying the core tech - the same one rumored to be working with Elon Musk.

It's tiny compared to Nvidia...

Yet it could be the fastest way to ride Trump's AI surge + Musk's next supercycle.

See the name and ticker before this goes mainstream.

---

The Cooper Companies, Inc. (NASDAQ: COO) operates as a leading global medical device company, carved out into two distinct, high-performing business units: CooperVision and CooperSurgical. Positioned within the Health Care Equipment & Supplies sub-industry, the company focuses on delivering innovative solutions that improve the quality of life for patients worldwide. From daily disposable contact lenses that correct vision and manage myopia to specialized medical devices and fertility solutions that support women's health, Cooper Companies has built a resilient business model designed to capture steady, recurring revenue streams. Despite a challenging macroeconomic environment and recent price action volatility, the company remains a critical player in the medical technology sector, attracting significant attention from long-term value and growth investors alike.

Business Model and Revenue Streams 📦

The Cooper Companies operates a highly specialized business model structured around two primary segments: CooperVision and CooperSurgical. CooperVision is a dominant force in the global contact lens market, manufacturing a wide array of soft contact lenses, including spherical, toric, and multifocal designs. A key driver of CooperVision’s revenue model is the structural shift toward daily disposable lenses, such as the premium MyDay product line. Daily disposables represent an exceptionally attractive business model for investors because they generate highly predictable, recurring revenue streams. Unlike traditional lenses that patients wear for months, daily disposables require continuous replenishment, creating a sticky customer base with high lifetime value. Additionally, CooperVision has pioneered the myopia management space with its MiSight daily child-friendly lenses, which are clinically proven to slow the progression of nearsightedness in children. This pediatric segment represents a high-margin, fast-growing niche that addresses a global epidemic of worsening eyesight.

On the other side of the business, CooperSurgical focuses on the women's health market, offering a comprehensive portfolio of medical devices, diagnostic products, and surgical instruments. A significant portion of CooperSurgical's revenue is tied to the fertility market, specifically in-vitro fertilization (IVF) clinics and laboratory equipment. As global demographics shift and maternal age increases, the structural demand for fertility treatments continues to grow. CooperSurgical provides the specialized media, micropipettes, and genetic testing services required to support these complex procedures. By catering to both the high-volume, recurring contact lens market and the specialized, high-value women's health and fertility markets, Cooper Companies achieves a balanced revenue mix that blends defensive stability with high-growth medical technology exposure.

However, operating a global medical device business means that Cooper Companies is highly sensitive to macroeconomic policies and international market dynamics. Interest rate policies enacted by global central banks directly impact the capital expenditure budgets of fertility clinics and hospital systems, which can influence the sales of CooperSurgical’s high-end laboratory equipment. Furthermore, trade policies and international regulatory approvals play a critical role in the company's ability to distribute its products globally. Because medical devices are subject to stringent regulatory oversight from bodies like the FDA in the United States and the European Medicines Agency in Europe, any changes in regulatory compliance standards can delay product launches or increase operational costs.

Global demand is also subject to regional economic conditions and consumer confidence. For instance, recent softness in the Japanese market has emerged as a key watch point for CooperVision, as Japan represents a major market for contact lens consumption. Similarly, the fertility market is partially dependent on consumer discretionary spending, as IVF treatments can be expensive and are not always fully covered by insurance. Consequently, economic downturns or periods of high inflation can cause patients to delay fertility procedures, introducing a degree of cyclicality to CooperSurgical's earnings. Currency fluctuations also present a persistent headwind; because Cooper sells its products in over 100 countries, a strong US dollar can negatively impact international revenue translation, particularly in regions experiencing currency depreciation, such as Japan.

Recent Performance and Corporate Developments 📈

Q1 2026 Financial Highlights: 💰

• Total Revenue: $1,024,099,999, representing a solid year-over-year growth rate of 6.16%, driven primarily by the continued adoption of premium contact lenses.
• Net Income: $130,800,000, showcasing the company's ability to maintain strong absolute profitability despite inflationary pressures on manufacturing and distribution costs.
• Diluted Earnings Per Share (EPS): $0.66 for the quarter ending January 31, 2026.
• Calculated Net Profit Margin: Approximately 12.77%, highlighting a robust conversion of top-line revenue into bottom-line profits.
• Average Daily Trading Volume: 2,081,274 shares, demonstrating deep market liquidity and active institutional participation.

Strategic Initiatives and Mergers: 🤝

Cooper Companies has continued to focus on organic product innovation and leadership optimization to sustain its competitive edge. On May 4, 2026, the company announced the appointment of Paul Keel to its Board of Directors. Keel, an experienced executive in the global medical device and industrial sectors, is expected to bring valuable operational expertise as Cooper navigates international supply chain complexities and expands its global footprint. This leadership addition aligns with the company's long-term strategy of driving operational efficiencies across both its vision and surgical divisions.

On the product front, CooperVision launched its "MADE BETTER" sustainability promise on April 9, 2026, beginning with its flagship MyDay contact lenses. This initiative reflects a growing trend in the medical device industry where sustainability and environmental responsibility are becoming key purchasing criteria for both healthcare providers and retail consumers. The program commits to responsible sourcing, more efficient manufacturing processes, and offsetting a portion of the company's plastic footprint. By integrating sustainability into its core product lines, Cooper is not only addressing environmental concerns but also strengthening its brand equity among eco-conscious consumers and institutional hospital networks that prioritize green procurement.

In terms of portfolio management, the company has taken minor steps to optimize its balance sheet and investment holdings. On April 17, 2026, Cooper trimmed its investment portfolio by selling 25,949 shares of Global-E Online for approximately $903,000 at an average price of $34.79 per share. This transaction represented a minor 0.68% reduction in direct holdings, demonstrating disciplined capital allocation. While there have been no major mergers or acquisitions finalized in the most recent quarter, the company remains highly focused on advancing its internal product pipeline, particularly ahead of the highly anticipated CooperSurgical Pipeline & Industry Showcase scheduled for October 15, 2026.

Profitability and Fair Value 🎯

Analyzing Cooper's profitability metrics reveals a company with a highly stable financial foundation, though it currently trades at a premium valuation that reflects its defensive growth profile. The company's trailing twelve-month (TTM) P/E ratio stands at 29.21, while its forward-looking FMP P/E ratio is slightly higher at 30.33. This indicates that the market is willing to pay a premium for Cooper's earnings, largely due to the highly recurring nature of its contact lens business and the structural growth drivers in women's health. With a TTM P/S ratio of 2.80 (and an FMP P/S of 2.91), the company is valued reasonably relative to its annual sales, especially when compared to other high-margin medical dental and supply peers like Straumann Holding AG (SAUHY).

The company's EV/EBITDA ratio of 15.02 further supports the view that Cooper is valued as a premium asset. However, the PEG ratio presents an interesting anomaly at -9.06. A negative PEG ratio typically indicates a temporary divergence between trailing earnings growth and forward projections, often caused by non-recurring charges, restructuring costs, or short-term margin compression from global supply chain adjustments. Given that Cooper's year-over-year revenue growth remains healthy at 6.16%, this negative PEG should not be viewed as a sign of structural decline, but rather as a reflection of short-term earnings volatility as the company absorbs macroeconomic headwinds and invests heavily in its product pipeline.

From a valuation perspective, the recent price action of Cooper Companies presents a compelling opportunity for value-oriented investors. The stock has experienced a one-year price decline of -28.11%, dropping to a cache price of $59.61. This significant pullback has occurred despite steady top-line growth and consistent profitability, suggesting that the sell-off may be overdone. Market analysts have frequently highlighted Cooper as a top value stock for the long term, noting that the pullback has compressed its valuation multiples to levels that historically represent attractive entry points. When compared to peers in the medical dental and supply space, Cooper’s robust cash generation and defensive product mix make its current price look highly fair, if not undervalued, for investors with a multi-year time horizon.

Analyst Estimates and Ratings 📊

Consensus Rating: Buy

Price Target: Not specified in the current research packet, but the stock has attracted strong buy-side support.

The investment community maintains a highly constructive outlook on Cooper Companies, recognizing its resilient business model and strong market positioning. The six-month analyst consensus currently stands at 0 Strong Buy, 6 Buy, 4 Hold, and 1 Sell. This positive sentiment is further reinforced by the latest street action, which rates the stock as Overweight. This newsletter screens for stocks with strong recent buy-side action, and Cooper's presence on this list highlights its appeal to institutional managers looking for high-quality medical device exposure.

While there have been no official analyst upgrades in the last 90 days, the stock's high average daily volume of over 2 million shares indicates that institutional liquidity remains robust. Analysts tracking the stock are particularly focused on the upcoming earnings releases, where any signs of margin expansion or stabilization in foreign markets could act as a catalyst for upward price target revisions.

Investor-Focused Takeaway: Is COO Right for Your Portfolio?

What to Watch in the Near Term: 📈

• The Q2 2026 Earnings Release on July 31, 2026, which will provide critical insights into CooperVision's growth momentum and the rate of MyDay and MiSight adoption.
• The stabilization of international markets, particularly whether the company can overcome recent softness in Japan and navigate ongoing volatility in the global fertility market.
• The CooperSurgical Pipeline & Industry Showcase on October 15, 2026, which could unveil new product innovations and serve as a medium-term catalyst for the stock.
• Operating margin progression and the management's ability to control manufacturing costs in an inflationary environment.

Recommendation:

The Cooper Companies, Inc. presents a balanced investment proposition that combines defensive, recurring revenue from its contact lens business with high-growth potential in the women's health and myopia management sectors. The stock's -28.11% price decline over the past year has created a highly attractive entry point, compressing its valuation multiples and positioning it as a premier value play within the medical device space. While near-term headwinds such as regional softness in Japan and macroeconomic uncertainty surrounding fertility spending warrant a measured approach, the company’s strong balance sheet, consistent 6.16% revenue growth, and robust institutional backing suggest that the long-term investment thesis remains firmly intact. For investors seeking a high-quality, liquid healthcare asset with a proven track record of profitability, Cooper Companies represents a compelling addition to a diversified portfolio.

The #1 Crypto of 2026 - "The Superpower Coin"

25X Predicted For THIS Crypto - Starting on March 24th

This tiny 3-cent crypto just partnered with 19 of the biggest companies in the world... from the largest world superpowers (US & China).

And one team of crypto experts has identified it as the most promising crypto of 2026.

You can see all of the details surrounding the #1 Crypto of 2026 here:

3-Cent Superpower Coin Here

---

Final Take: The Logistics Backbone and Specialized Tech Powering Global Healthcare

The healthcare revolution isn't just about high-risk biotech trials and headline-grabbing drug discoveries — it's about execution at the point of care. And that requires two things: the physical infrastructure to keep global medical facilities running and the specialized devices that improve daily patient outcomes.

That's where Medline Inc. (MDLN) and The Cooper Companies (COO) stand apart.

🏥 Medline Inc. (MDLN) — The Indispensable Supply Chain Backbone of Global Healthcare

✔ Dual-threat business model acting as both a high-volume medical device manufacturer and a world-class logistics powerhouse

✔ Deeply integrated into the daily workflows of thousands of healthcare systems globally, making switching costs incredibly high

✔ Highly resilient, volume-driven revenue model that scales alongside the baseline demands of aging global demographics

➤ Best for: Investors seeking defensive, cash-generative exposure to the essential physical infrastructure and supply chain of the global healthcare system.

👁️ The Cooper Companies, Inc. (COO) — The High-Margin Specialist in Vision and Women’s Health

✔ Dual-engine growth driven by dominant market positions in contact lenses (CooperVision) and specialized fertility solutions (CooperSurgical)

✔ High-barrier-to-entry product portfolios that generate highly predictable, recurring subscription-like revenue streams

✔ Resilient financial profile capable of navigating macroeconomic volatility due to the non-discretionary nature of vision correction and reproductive care

➤ Best for: Growth-oriented investors looking for a high-moat medical technology leader with pricing power and structural demographic tailwinds.

Investor Insight

🧩 Want defensive, high-volume healthcare logistics with absolute market integration? → MDLN

⚙️ Want high-margin, specialized medical devices with recurring consumer demand? → COO

Bottom Line:

Healthcare doesn't function without the physical tools of the trade. While medical systems rely on Medline to keep their clinical shelves stocked with essential surgical and diagnostic equipment, millions of patients rely on Cooper Companies for daily vision correction and critical reproductive care.

As the global population ages and healthcare systems prioritize operational efficiency, MDLN and COO aren't speculative bets — they are the foundational infrastructure of modern medicine.

Not investment advice. Do your own research.